The approval applies to anyone aged 18 and older who has a risk of being exposed to the virus. But the FDA and the Centers ...

Chikungunya is transmitted to humans through the bite of infected female mosquitoes, particularly Aedes aegypti and Aedes albopictus. It is a ...

The use of Valneva’s chikungunya vaccine, known under the brand name Ixchiq, has been paused in elderly individuals after reports of serious adverse events (AEs) The US Food and Drug ...

With this extension, IXCHIQ ®, the first vaccine against the ... M.D., Chief Medical Officer of Valneva, said, “Given the substantial risk that chikungunya presents to individuals residing ...

The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events. As of May 7, 17 serious events, including two deaths, have been reported ...

Valneva has been awarded funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and EU to expand access to its recently approved vaccine for chikungunya, a potentially life ...

17 serious adverse events, including two deaths, reported among adults 62–89 who received the Ixchiq vaccine. Ixchiq was approved in 2023 and has been distributed globally with 80,000 doses ...

The FDA and the Centers for Disease Control and Prevention (CDC) have jointly recommended pausing the use of Valneva’s chikungunya vaccine Ixchiq in the United States amid ongoing investigations into ...

Europe Reviews Valneva's Chikungunya Vaccine After Reports of Serious Side Effects (Reuters) -The European Union's health regulator said on Wednesday it was reviewing French drugmaker Valneva's ...

(Reuters) - The U.S. Centers for Disease Control and Prevention has accepted its advisory panel's recommendations on vaccines ...

HEALTH. ED TO YOU. LET’S PICK IT UP RIGHT THERE. MARIA. HERE TO DISCUSS SOME MORE. IS DOCTOR TODD AND FAMILIAR FACE HERE AT 430 ON NEWSCENTER 5. CHIEF OF INFECTIOUS DISEASES AT SOUTH SHORE HEALTH.

This new agreement complements the license agreement Valneva signed in 2021 with Instituto Butantan in Brazil for the development, manufacturing and marketing of a local chikungunya vaccine at an ...